\documentclass[11pt,twoside]{article}\makeatletter

\IfFileExists{xcolor.sty}%
  {\RequirePackage{xcolor}}%
  {\RequirePackage{color}}
\usepackage{colortbl}
\usepackage{wrapfig}
\usepackage{ifxetex}
\ifxetex
  \usepackage{fontspec}
  \usepackage{xunicode}
  \catcode`⃥=\active \def⃥{\textbackslash}
  \catcode`❴=\active \def❴{\{}
  \catcode`❵=\active \def❵{\}}
  \def\textJapanese{\fontspec{Noto Sans CJK JP}}
  \def\textChinese{\fontspec{Noto Sans CJK SC}}
  \def\textKorean{\fontspec{Noto Sans CJK KR}}
  \setmonofont{DejaVu Sans Mono}
  
\else
  \IfFileExists{utf8x.def}%
   {\usepackage[utf8x]{inputenc}
      \PrerenderUnicode{–}
    }%
   {\usepackage[utf8]{inputenc}}
  \usepackage[english]{babel}
  \usepackage[T1]{fontenc}
  \usepackage{float}
  \usepackage[]{ucs}
  \uc@dclc{8421}{default}{\textbackslash }
  \uc@dclc{10100}{default}{\{}
  \uc@dclc{10101}{default}{\}}
  \uc@dclc{8491}{default}{\AA{}}
  \uc@dclc{8239}{default}{\,}
  \uc@dclc{20154}{default}{ }
  \uc@dclc{10148}{default}{>}
  \def\textschwa{\rotatebox{-90}{e}}
  \def\textJapanese{}
  \def\textChinese{}
  \IfFileExists{tipa.sty}{\usepackage{tipa}}{}
\fi
\def\exampleFont{\ttfamily\small}
\DeclareTextSymbol{\textpi}{OML}{25}
\usepackage{relsize}
\RequirePackage{array}
\def\@testpach{\@chclass
 \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else
  \ifnum \@lastchclass=7 5 \else
   \ifnum \@lastchclass=8 \tw@ \else
    \ifnum \@lastchclass=9 \thr@@
   \else \z@
   \ifnum \@lastchclass = 10 \else
   \edef\@nextchar{\expandafter\string\@nextchar}%
   \@chnum
   \if \@nextchar c\z@ \else
    \if \@nextchar l\@ne \else
     \if \@nextchar r\tw@ \else
   \z@ \@chclass
   \if\@nextchar |\@ne \else
    \if \@nextchar !6 \else
     \if \@nextchar @7 \else
      \if \@nextchar (8 \else
       \if \@nextchar )9 \else
  10
  \@chnum
  \if \@nextchar m\thr@@\else
   \if \@nextchar p4 \else
    \if \@nextchar b5 \else
   \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi
   \fi \fi  \fi  \fi  \fi  \fi  \fi \fi \fi \fi \fi \fi}
\gdef\arraybackslash{\let\\=\@arraycr}
\def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}}
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\def\abbr{}
\def\corr{}
\def\expan{}
\def\gap{}
\def\orig{}
\def\reg{}
\def\ref{}
\def\sic{}
\def\persName{}\def\name{}
\def\placeName{}
\def\orgName{}
\def\textcal#1{{\fontspec{Lucida Calligraphy}#1}}
\def\textgothic#1{{\fontspec{Lucida Blackletter}#1}}
\def\textlarge#1{{\large #1}}
\def\textoverbar#1{\ensuremath{\overline{#1}}}
\def\textquoted#1{‘#1’}
\def\textsmall#1{{\small #1}}
\def\textsubscript#1{\@textsubscript{\selectfont#1}}
\def\textxi{\ensuremath{\xi}}
\def\titlem{\itshape}
\newenvironment{biblfree}{}{\ifvmode\par\fi }
\newenvironment{bibl}{}{}
\newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par }
\newenvironment{citbibl}{}{\ifvmode\par\fi }
\newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi }
\newenvironment{docDate}{}{\ifvmode\par\fi }
\newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi }
\newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par }
\newenvironment{msHead}{\vskip 6pt}{\par}
\newenvironment{msItem}{\vskip 6pt}{\par}
\newenvironment{rubric}{}{}
\newenvironment{titlePart}{}{\par }

\newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}}
\newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}}
\newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}}
\newcolumntype{P}[1]{){\arraybackslash}p{#1}}
\newcolumntype{B}[1]{){\arraybackslash}b{#1}}
\newcolumntype{M}[1]{){\arraybackslash}m{#1}}
\definecolor{label}{gray}{0.75}
\def\unusedattribute#1{\sout{\textcolor{label}{#1}}}
\DeclareRobustCommand*{\xref}{\hyper@normalise\xref@}
\def\xref@#1#2{\hyper@linkurl{#2}{#1}}
\begingroup
\catcode`\_=\active
\gdef_#1{\ensuremath{\sb{\mathrm{#1}}}}
\endgroup
\mathcode`\_=\string"8000
\catcode`\_=12\relax

\usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry}
\usepackage{framed}

\definecolor{shadecolor}{gray}{0.95}
\usepackage{longtable}
\usepackage[normalem]{ulem}
\usepackage{fancyvrb}
\usepackage{fancyhdr}
\usepackage{graphicx}
\usepackage{marginnote}

\renewcommand{\@cite}[1]{#1}


\renewcommand*{\marginfont}{\itshape\footnotesize}

\def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif}

  \pagestyle{fancy}

\usepackage[pdftitle={Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc. (USA)},
 pdfauthor={}]{hyperref}
\hyperbaseurl{}

	 \paperwidth210mm
	 \paperheight297mm
              
\def\@pnumwidth{1.55em}
\def\@tocrmarg {2.55em}
\def\@dotsep{4.5}
\setcounter{tocdepth}{3}
\clubpenalty=8000
\emergencystretch 3em
\hbadness=4000
\hyphenpenalty=400
\pretolerance=750
\tolerance=2000
\vbadness=4000
\widowpenalty=10000

\renewcommand\section{\@startsection {section}{1}{\z@}%
     {-1.75ex \@plus -0.5ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large\bfseries}}
\renewcommand\subsection{\@startsection{subsection}{2}{\z@}%
     {-1.75ex\@plus -0.5ex \@minus- .2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large}}
\renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}%
     {-1.5ex\@plus -0.35ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\large}}
\renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}%
     {-1ex \@plus-0.35ex \@minus -0.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\normalsize}}
\renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}%
     {1.5ex \@plus1ex \@minus .2ex}%
     {-1em}%
     {\reset@font\normalsize\bfseries}}


\def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt}
 \@tempdima 1.5em \begingroup
 \parindent \z@ \rightskip \@pnumwidth 
 \parfillskip -\@pnumwidth 
 \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par
 \endgroup}
\def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}}
\def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}}
\def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}}
\def\l@subparagraph{\@dottedtocline{5}{10em}{5em}}
\@ifundefined{c@section}{\newcounter{section}}{}
\@ifundefined{c@chapter}{\newcounter{chapter}}{}
\newif\if@mainmatter 
\@mainmattertrue
\def\chaptername{Chapter}
\def\frontmatter{%
  \pagenumbering{roman}
  \def\thechapter{\@roman\c@chapter}
  \def\theHchapter{\roman{chapter}}
  \def\thesection{\@roman\c@section}
  \def\theHsection{\roman{section}}
  \def\@chapapp{}%
}
\def\mainmatter{%
  \cleardoublepage
  \def\thechapter{\@arabic\c@chapter}
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \pagenumbering{arabic}
  \setcounter{secnumdepth}{6}
  \def\@chapapp{\chaptername}%
  \def\theHchapter{\arabic{chapter}}
  \def\thesection{\@arabic\c@section}
  \def\theHsection{\arabic{section}}
}
\def\backmatter{%
  \cleardoublepage
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \setcounter{secnumdepth}{2}
  \def\@chapapp{\appendixname}%
  \def\thechapter{\@Alph\c@chapter}
  \def\theHchapter{\Alph{chapter}}
  \appendix
}
\newenvironment{bibitemlist}[1]{%
   \list{\@biblabel{\@arabic\c@enumiv}}%
       {\settowidth\labelwidth{\@biblabel{#1}}%
        \leftmargin\labelwidth
        \advance\leftmargin\labelsep
        \@openbib@code
        \usecounter{enumiv}%
        \let\p@enumiv\@empty
        \renewcommand\theenumiv{\@arabic\c@enumiv}%
	}%
  \sloppy
  \clubpenalty4000
  \@clubpenalty \clubpenalty
  \widowpenalty4000%
  \sfcode`\.\@m}%
  {\def\@noitemerr
    {\@latex@warning{Empty `bibitemlist' environment}}%
    \endlist}

\def\tableofcontents{\section*{\contentsname}\@starttoc{toc}}
\parskip0pt
\parindent1em
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\newenvironment{reflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemsep}{0pt}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\itshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{sansreflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\itemsep}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\upshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{specHead}[2]%
 {\vspace{20pt}\hrule\vspace{10pt}%
  \phantomsection\label{#1}\markright{#2}%

  \pdfbookmark[2]{#2}{#1}%
  \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}%
  }{}
      \def\TheFullDate{2016-01-15 (revised: 15 January 2016)}
\def\TheID{\makeatother }
\def\TheDate{2016-01-15}
\title{Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc. (USA)}
\author{}\makeatletter 
\makeatletter
\newcommand*{\cleartoleftpage}{%
  \clearpage
    \if@twoside
    \ifodd\c@page
      \hbox{}\newpage
      \if@twocolumn
        \hbox{}\newpage
      \fi
    \fi
  \fi
}
\makeatother
\makeatletter
\thispagestyle{empty}
\markright{\@title}\markboth{\@title}{\@author}
\renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@
\belowdisplayskip \abovedisplayskip
\abovedisplayshortskip \z@ plus2\p@
\belowdisplayshortskip 4\p@ plus2\p@ minus2\p@
\def\@listi{\leftmargin\leftmargini
               \topsep 2\p@ plus1\p@ minus1\p@
               \parsep 2\p@ plus\p@ minus\p@
               \itemsep 1pt}
}
\makeatother
\fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm}
\fancyhf{} 
\setlength{\headheight}{14pt}
\fancyhead[LE]{\bfseries\leftmark} 
\fancyhead[RO]{\bfseries\rightmark} 
\fancyfoot[RO]{}
\fancyfoot[CO]{\thepage}
\fancyfoot[LO]{\TheID}
\fancyfoot[LE]{}
\fancyfoot[CE]{\thepage}
\fancyfoot[RE]{\TheID}
\hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true}
\fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}}

\date{}
\usepackage{authblk}

\providecommand{\keywords}[1]
{
\footnotesize
  \textbf{\textit{Index terms---}} #1
}

\usepackage{graphicx,xcolor}
\definecolor{GJBlue}{HTML}{273B81}
\definecolor{GJLightBlue}{HTML}{0A9DD9}
\definecolor{GJMediumGrey}{HTML}{6D6E70}
\definecolor{GJLightGrey}{HTML}{929497} 

\renewenvironment{abstract}{%
   \setlength{\parindent}{0pt}\raggedright
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
   \textcolor{GJBlue}{\large\bfseries\abstractname\space}
}{%   
   \vskip8pt
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
}

\usepackage[absolute,overlay]{textpos}

\makeatother 
      \usepackage{lineno}
      \linenumbers
      
\begin{document}

             \author[1]{Ismat Abedlrhman Alborhan  Mohammed}

             \affil[1]{  Cardiff University}

\renewcommand\Authands{ and }

\date{\small \em Received: 8 December 2015 Accepted: 1 January 2016 Published: 15 January 2016}

\maketitle


\begin{abstract}
        


Introduction-The most widely recognized neuropathic syndrome found in individuals with diabetes is diabetic peripheral neuropathy. Diabetes is the commonest reason for neuropathy around the world, creating an extensive range of disorders including diverse forms of nerves and pathological mechanisms such as ischemic, metabolic, compressive and immunologic.12 There are different forms of diabetic neuropathies (diffuse or focal) which present with various clinical sign and influencing distinctive parts of the nervous system. The common forms of neuropathies are autonomic neuropathies and chronic sensorimotor distal symmetric polyneuropathy (DPN). Diagnosis of DPN is reached by excluding other disorder that exhibits the same signs.3 Approximately, 8% of general population suffer from long standing pain are caused by the neuropathic pain.4 Around 50% of chronic diabetics? individuals (more than 25 years) will develop neuropathy which affect their daily living.5 Hyperglycaemia is the chief reason of advancement of all neuropathies, counting PDN. The Diabetes Control and Complications Trial (DCCT) demonstrated that good glycaemic control will lessen the occurrence of neuropathy up to 60%.6

\end{abstract}


\keywords{}

\begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) 
\textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark}
\end{textblock*}

\begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) 
\textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}}
\end{textblock*}


\let\tabcellsep& 	 	 		 
\section[{Describe the Various Types of Neuropathy}]{Describe the Various Types of Neuropathy}\par
Observed in Patients with Diabetes Ismat Abedlrhman Alborhan Mohammed he most widely recognized neuropathic syndrome found in individuals with diabetes is diabetic peripheral neuropathy. Diabetes is the commonest reason for neuropathy around the world, creating an extensive range of disorders including diverse forms of nerves and pathological mechanisms such as ischemic, metabolic, compressive and immunologic. \hyperref[b10]{12} There are different forms of diabetic neuropathies (diffuse or focal) which present with various clinical sign and influencing distinctive parts of the nervous system. The common forms of neuropathies are autonomic neuropathies and chronic sensorimotor distal symmetric polyneuropathy (DPN). Diagnosis of DPN is reached by excluding other disorder that exhibits the same signs. \hyperref[b2]{3} Approximately, 8\% of general population suffer from long standing pain are caused by the neuropathic pain. \hyperref[b3]{4} Around 50\% of chronic diabetics' individuals (more than 25 years) will develop neuropathy which affect their daily living. \hyperref[b4]{5} Hyperglycaemia is the chief reason of advancement of all neuropathies, counting PDN. The Diabetes Control and Complications Trial (DCCT) demonstrated that good glycaemic control will lessen the occurrence of neuropathy up to 60\%. \hyperref[b5]{6} The pain accompanying with PDN is often refer to as numbness, tingling pain, or augmented due to touch. It may also be labelled as electrical, burning, or stabbing with paraesthesia, deep aching and hyperesthesia. The pain is classically more at night-time. PDN characteristically progresses in the lower legs and feet. Allodynia (excruciating sensations to mild stimuli) and hyperalgesia (augmented sensitivity to painful sensations) may also develop.  {\ref 78} Warning sign of nerve impairment may comprise: \hyperref[b7]{9} ? Tingling and numbness, or pain in the toes, arms, legs feet and hands ? hands and feet muscle wasting ? Nausea, or vomiting ? Constipation or diarrhoea ? Faintness or dizziness due to postural hypotension ? Urinary problems ? Erectile dysfunction in men or vaginal dryness in women\par
Author: Cardiff University. e-mail: asmatme@hotmail.com 
\section[{? weakness}]{? weakness}\par
Approximately, 20\% of all diabetic persons and about a third of individuals with DPN are suffer from painful symptoms like tingling, burning (paraesthesia or 'pins and needles'), shooting or stabbing.  {\ref 1011} The diabetic peripheral neuropathy pathophysiology still not fully understood. A few studies have shown that the ideal way to avert or deferral diabetic peripheral neuropathy is a close control of glycaemia. \hyperref[b10]{12} Numerous theories of pathogenesis have been distinguished in the aetiology of DN such as: \hyperref[b11]{13} ? Oxidative-nitrosative stress? Neuroinflammation ? Mitochondrial dysfunction ? Bioenergetic crisis ? Axon-glia interactions ? Demyelination\par
Some recent studies have demonstrated that nearly 30\% of diabetic patients are influenced by distal symmetric polyneuropathy. In T1DM patient, the EURODIAB prospective complications study found a prevalence rate of 28\% for distal symmetrical polyneuropathy. \hyperref[b12]{14} Theories concerning the numerous aetiologies of diabetic neuropathy comprise: \hyperref[b13]{15} ? Nerve fibers injury by metabolic disorder. ? Insufficiency of nerve and blood vessels ? Impaired autoimmune ? Deficient of neurohormonal growth factor Nevertheless, Current studies have demonstrated that both metabolic interactions and vascular factors are included at all steps of DPN. \hyperref[b14]{16}  The exact mechanisms creating DSP are unknown, yet are without a doubt depend on a number of factors and involve pathological changes due to reduced typical levels of blood glucose, the utmost noticeable of which includes augmented creation of free radicals due to hyperglycaemia-stimulated oxidative stress. The main demonstrated management that successfully defers the start or development of DSP is tight glycaemic control. However, DSP sooner or later precede in many diabetic's individuals in spite of good glycaemic control. Diabetes makes persons vulnerable to focal peripheral neuropathies including single nerves and nerve roots. The most recurrently affected cranial nerve is the oculomotor nerve which appears as incomplete oculomotor nerve palsy with pupillary sparing. Moreover, problem such as a unilateral truncal (thoracic) radiculopathy, display with acute abdominal or chest pain. Diabetes also leads to other peripheral nerve entrapments such as, median, ulnar, lateral femoral cutaneous, radial, and plantar nerves.  {\ref 25} Despite the fact that it stays unsubstantiated whether tight glycaemic control can turn around pre-existing autonomic and peripheral nervous system injury brought on by type 1 diabetes, the sooner we perform intensive treatment, the more successfully we counteract future complications, involving neuropathy.  {\ref 26}  
\section[{Diabetic|Neuropathy|Classification|Types|Causes}]{Diabetic|Neuropathy|Classification|Types|Causes}\par
Risk Factors|Signs|Symptoms|Treatment [Internet].\par
[cited 2016 Apr 13] \begin{figure}[htbp]
\noindent\textbf{}\includegraphics[]{image-2.png}
\caption{\label{figure2}}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{} \par 
\begin{longtable}{P{0.85\textwidth}}
Year 2016\\
Volume XVI Issue V Version I\\
D D D D ) F\\
(\end{longtable} \par
  {\small\itshape [Note: . Available from: http://www. epainassist.com/nerves/diabetic-neuropathy 22.]} 
\caption{\label{tab_1}}\end{figure}
 			\footnote{© 2016 Global Journals Inc. (US)} 		 		\backmatter  			  				\begin{bibitemlist}{1}
\bibitem[Rauck et al. ()]{b6}\label{b6} 	 		‘Controlled Trial of Gabapentin Enacarbil in Subjects with Neuropathic Pain Associated with Diabetic Peripheral Neuropathy’.  		 			R Rauck 		,  		 			C W Makumi 		,  		 			S Schwartz 		,  		 			O Graff 		,  		 			G Meno-Tetang 		,  		 			C F Bell 		.  	 	 		\textit{Pain Pract}  		2013. 13 p. .  	 
\bibitem[Diabetes Mellitus and Its Degenerative Complications: A Prospective Study of 4,400 Patients Observed Between 1947 and 1973 Diabetes Care (July/August 1978 1)]{b4}\label{b4} 	 		\textit{Diabetes Mellitus and Its Degenerative Complications: A Prospective Study of 4,400 Patients Observed Between 1947 and 1973 Diabetes Care},  		 \xref{http://dx.doi.org/10.2337/diacare.1.4.252}{10.2337/diacare.1.4.252}.  		July/August 1978 1. p. .  	 
\bibitem[Vinik et al. (2003)]{b13}\label{b13} 	 		\textit{Diabetic Autonomic Neuropathy. Diabetes Care},  		 			A I Vinik 		,  		 			R E Maser 		,  		 			B D Mitchell 		,  		 			R Freeman 		.  		 \url{http://care.diabetesjournals.org/content/26/5/1553.full\#cited-by}  		2003 May 1. 2015 Nov 26. 26 p. .  	 	 (Internet) 
\bibitem[Sinnreich et al. ()]{b1}\label{b1} 	 		‘Diabetic neuropathies. Classification, clinical features, and pathophysiological basis’.  		 			M Sinnreich 		,  		 			B V Taylor 		,  		 			P J Dyck 		.  	 	 		\textit{Neurologist}  		2005. 11 p. .  	 
\bibitem[Boulton et al. (2005)]{b2}\label{b2} 	 		\textit{Diabetic Neuropathies: A statement by the American Diabetes Association Diabetes Care},  		 			Ajm Boulton 		,  		 			A I Vinik 		,  		 			J C Arezzo 		,  		 			V Bril 		,  		 			E L Feldman 		,  		 			R Freeman 		.  		 doi:10.2337/ diacare.28.4.956.  		April 2005. 28 p. .  	 
\bibitem[Diabetic Neuropathies: The Nerve Damage of Diabetes|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)]{b7}\label{b7} 	 		\textit{Diabetic Neuropathies: The Nerve Damage of Diabetes|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)},  		 	 	 (Internet) 
\bibitem[Bansal et al. ()]{b18}\label{b18} 	 		‘Diabetic neuropathy’.  		 			V Bansal 		,  		 			J Kalita 		,  		 			U K Misra 		.  	 	 		\textit{Postgrad Med J}  		2006. 82 p. .  	 
\bibitem[Ziegler et al. (2014)]{b16}\label{b16} 	 		‘Diabetic neuropathy’.  		 			D Ziegler 		,  		 			J Keller 		,  		 			C Maier 		,  		 			J Pannek 		.  	 	 		\textit{Exp Clin Endocrinol Diabetes}  		2014 Jul 1. 122  (7)  p. .  	 
\bibitem[Smith and Torrance ()]{b3}\label{b3} 	 		‘Epidemiology of neuropathic pain and its impact on quality of life’.  		 			B H Smith 		,  		 			N Torrance 		.  	 	 		\textit{Curr Pain Headache Rep}  		2012. 16 p. .  	 
\bibitem[Farvid and Homayooni ()]{b10}\label{b10} 	 		‘Improving neuropathy scores in type 2 diabetic patients using micronutrients supplementation’.  		 			M S Farvid 		,  		 			F Homayooni 		.  	 	 		\textit{J Diabetes}  		2011. 3 p. 260.  	 
\bibitem[Tracy et al. ()]{b0}\label{b0} 	 		‘Microvasculitis in diabetic lumbosacral radiculoplexus neuropathy’.  		 			J A Tracy 		,  		 			J K Engelstad 		,  		 			P J Dyck 		.  	 	 		\textit{J Clin Neuromuscul Dis}  		2009. 11 p. .  	 
\bibitem[Tesfaye et al. ()]{b15}\label{b15} 	 		‘Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management’.  		 			S Tesfaye 		,  		 			L Vileikyte 		,  		 			G Rayman 		.  	 	 		\textit{Diabetes Metab Res Rev}  		2011. p. .  	 
\bibitem[Tesfaye ()]{b8}\label{b8} 	 		‘Recent advances in the management of diabetic symmetrical polyneuropathy’.  		 			S Tesfaye 		.  	 	 		\textit{J Diabetes Invest}  		2010. 2 p. .  	 
\bibitem[Tesfaye et al. ()]{b12}\label{b12} 	 		‘The prevalence of diabetic neuropathy and its relation to glycemic control and potential risk factors: the EURODIAB IDDM Complications Study’.  		 			S Tesfaye 		,  		 			L Stephens 		,  		 			J Stephenson 		.  	 	 		\textit{Diabetologia}  		1996. 39 p. .  	 
\bibitem[Davies et al. ()]{b9}\label{b9} 	 		‘The prevalence, severity and impact of painful diabetic peripheral neuropathy in type 2 diabetes’.  		 			M Davies 		,  		 			S Brophy 		,  		 			R Williams 		,  		 			A Taylor 		.  	 	 		\textit{Diabetes Care}  		2006. 29 p. .  	 
\bibitem[The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group JAMA ()]{b5}\label{b5} 	 		‘The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group’.  		 \xref{http://dx.doi.org/10.1001/jama.287.19.2563}{10.1001/jama.287.19.2563}.  	 	 		\textit{JAMA}  		2002. 287  (19)  p. .  	 	 (Effect of Intensive Therapy on the Microvascular Complications of Type 1 Diabetes Mellitus) 
\bibitem[Smith and Singleton ()]{b17}\label{b17} 	 		‘This is an excellent and detailed review of DN’.  		 			A G Smith 		,  		 			J R Singleton 		.  	 	 		\textit{Continuum}  		2012. 18 p. .  	 	 (Diabetic neuropathy) 
\bibitem[Cameron et al. ()]{b14}\label{b14} 	 		‘Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy’.  		 			N A Cameron 		,  		 			S E Eaton 		,  		 			M A Cotter 		,  		 			S Tesfaye 		.  	 	 		\textit{Diabetologia}  		2001. 44  (11)  p. .  	 
\bibitem[Baron and Binder ()]{b11}\label{b11} 	 		‘Wasne Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment’.  		 			R Baron 		,  		 			A Binder 		,  		 			G 		.  	 	 		\textit{Lancet Neurol}  		2010. 9 p. .  	 
\end{bibitemlist}
 			 		 	 
\end{document}